A bone-building drug did not speed pelvic fracture healing

Abaloparatide, a bone-building drug approved to prevent osteoporotic fractures, did not accelerate the healing of pelvic fractures in a randomised, placebo-controlled trial — and by one measure, healing numerically favoured placebo [s1]. The result is a useful check on an intuitive idea: that a drug which builds bone should also help a broken bone knit faster.

The intuition is not unreasonable. Abaloparatide is an anabolic agent — it stimulates bone formation rather than merely slowing its breakdown — and in postmenopausal osteoporosis it produces some of the largest gains in bone mineral density of any available treatment, ranking ahead of the antiresorptive drugs at the spine and femoral neck in a recent network meta-analysis of 23 randomised trials [s2]. Turning that bone-forming action toward an acute fracture, to speed repair and shorten the weeks of pain and immobility a pelvic break causes, has been an open question. This trial tested it directly [s1].

What the trial did

The study enrolled 48 adults — postmenopausal women and men aged 50 or older — within four weeks of a pelvic fracture, and randomised them to blinded abaloparatide or placebo [s1]. This was a frail, elderly group: mean age 82, 93% women, 98% with multiple pelvic-ring fractures, 67% with a sacral fracture and 36% with at least one displaced fracture [s1]. The primary endpoint was fracture healing at three months, graded by two radiologists on CT scans using a five-point scale for cortical bridging — how much of the broken bone's outer shell had re-connected — with treatment starting within four weeks of the injury [s1].

There was no significant difference. The distribution of bridging scores did not separate between groups (p = 0.15), and the result held when the 81 individual fractures were analysed rather than patients (p = 0.13) [s1]. When patients were sorted simply into healed or not, 39% healed on abaloparatide against 64% on placebo — a relative risk of 0.61 with a confidence interval, 0.33 to 1.12, that crosses 1 and so does not establish a real difference in either direction [s1]. Analysed by individual fracture, the split was 47% versus 53% (relative risk 0.88, 0.55 to 1.40) [s1].

The drug did not help pain or function either. Physical-performance and mobility scores improved over time in both groups, with no separation between them, and after accounting for a higher baseline pain score in the placebo arm there was no further group difference in how pain changed [s1].

How to read a null this small

The honest headline is a null result, and the trial's own limits are the first thing to state. With just 48 patients it was small, and the authors describe it as such [s1]. The eye-catching 39%-versus-64% split is exactly the kind of number a small trial throws off by chance: the wide confidence interval means it is compatible with a modest benefit, no effect, or a modest harm, and it should not be read as evidence that the drug slows healing [s1]. What the trial can say is that it found no signal that abaloparatide speeds pelvic fracture healing over three months, across radiological, pain and functional measures alike [s1].

That matters because the plausible upside was being weighed against real costs — a daily injectable given to frail, mostly very elderly patients — and a null in a well-conducted, blinded trial is the result that keeps an unproven use from drifting into practice on mechanism alone. It does nothing to undercut the drug's established role in raising bone density to prevent future fractures, which is a different question answered by different, larger trials [s2].

The finding sits alongside a broader, sobering pattern in bone medicine: drugs that reliably change bone density on a scan do not automatically deliver the downstream outcome patients actually want, whether that is a faster or larger response than an existing agent or the simpler goal of fewer fractures from everyday measures like diet. For older adults facing a pelvic fracture — a group whose fracture risk is itself often under-recognised — this trial narrows, rather than widens, what an anabolic drug can be expected to do. This article describes trial findings and is not medical advice.